- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03547622
Galantamine and CBT4CBT Pilot to Prevent Relapse.
Pilot Study of Galantamine and CBT4CBT to Reduce Post-taper Relapse for MAT
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized pilot study to examine the potential use of galantamine as an adjunct to the standard buprenorphine or methadone taper in the context of behavioral support. Early abstinence from opioids is associated with high relapse rates and there is a great need to develop interventions that will prevent relapse to opioid use.
In this randomized pilot, 30 adults enrolled in the methadone or buprenorphine maintenance programs at the APT Foundation and who have sought a medically supervised, voluntary taper from these medications will be offered participation in a double-blind, placebo controlled, randomized trial of galantamine as an adjunct to standard tapering procedures at this clinic along with the combined approach utilizing concurrent behavior therapy. Primary outcomes will be: (1) successful completion of taper (achieving a methadone/buprenorphine dose of 0), (2) opioid withdrawal symptoms, and (3) opioid use, assessed by self-report and urine samples during and up to 3 months after the end of opioid taper. The investigators will also closely monitor patient comfort and safety (assessed by opioid withdrawal symptoms, adverse events, with measures of stress, sleep and pain) as well as cognitive function (assessed by the CANTAB).
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- APT Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are male and females, between the ages of 18 and 65
- Are enrolled in the APT methadone or buprenorphine program, have been stabilized for at least one year, and who voluntarily wish to taper off MAT.
- For women of child-bearing age, have a negative serum pregnancy test at screening, agree to adequate contraception to prevent pregnancy, and agree to have monthly urine pregnancy tests at the clinic.
- Are fluent in English and have a 6th grade or higher reading level.
- Can commit to at least 12 weeks of treatment and are willing to be randomized to treatment
Exclusion Criteria:
- Are undergoing administrative (non-voluntary) tapering (e.g., example due to non-payment of program fees, program rule infractions).
- Meet DSM-V psychiatric classifications for lifetime schizophrenia or bipolar disorder, or have a depressive or anxiety disorder with current use of a prescribed psychotropic medication that cannot be discontinued;
- Current DSM-V diagnosis of drug or alcohol use disorder (other than opioids or tobacco);
- Demonstrate significant medical conditions, including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances or any other medical conditions that the study physician deems contraindicated for galantamine treatment;
- Use of other medications including a) drugs that slow heart rate (e.g., beta-blockers),which may increase the risk of bradycardia and AV block and b) NSAIDs; increased potential for developing ulcers/active or occult gastrointestinal bleeding;
- Have a screening liver function test (AST or ALT) greater than 3 times normal;
- Known allergy or adverse reaction to galantamine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: MAT taper with galantamine
Following initial MAT taper, participants will be given up to 16mg daily of galantamine for up to 10 weeks of the active study
|
Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
Other Names:
|
PLACEBO_COMPARATOR: MAT taper with placebo
Following initial MAT taper, participants will be given up to 16mg daily of placebo for up to 10 weeks of the active study
|
Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Methadone/Buprenorphine Dose to 0 mg for Successful Completion of Taper
Time Frame: during 10 weeks of study and up to 3 months after the end of opioid taper
|
Number of participants who were able to taper to 0 mg from methadone or buprenorphine over 10 weeks of treatment. Data about current medication and dose in mg was collected at the start of treatment (week 1) was recorded on a weekly medical sheet. Data was then collected weekly from participant self-report and verified through the clinic database. |
during 10 weeks of study and up to 3 months after the end of opioid taper
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Opioid Withdrawal Scale (COWS)
Time Frame: Data at week 0 (baseline) and week 10 (post treatment)
|
opioid withdrawal score at week 0 (baseline) and at 10 weeks (post treatment). 11-item scale designed to be administered by a clinician. Rates common signs and symptoms of opiate withdrawal and can be monitored over time. The summed score for the complete scale can be used to help clinicians determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. Score of 5-12 = mild; 13-24=moderate; 25-36=moderately severe; more than 36=severe withdrawal (Scale of 0 to 40). |
Data at week 0 (baseline) and week 10 (post treatment)
|
Substance Use Calendar
Time Frame: during 10 weeks of study
|
number of days of opioid use, assessed by self-report
|
during 10 weeks of study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathleen M Carroll, PhD, Yale University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Recurrence
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Parasympathomimetics
- Galantamine
Other Study ID Numbers
- 2000021868
- 2P50DA009241-21 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methadone or Buprenorphine Detoxoxification
-
University of Vermont Medical CenterNational Institute on Drug Abuse (NIDA)CompletedCigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid DependenceUnited States
-
University of PennsylvaniaNational Institute of Drug Abuse; The Wistar Institute; Ho Chi Minh City CDC; Institute...RecruitingInflammation | Opioid-use Disorder | HIV-1-infection | Immune Activation | Buprenorphine | Methadone | Naltrexone | Antiretroviral TreatmentUnited States, Vietnam
-
Saskatchewan Health Authority - Regina AreaGilead SciencesUnknownHepatitis C, Chronic | HIV/AIDS | Bone Diseases, Metabolic | Opioid Dependence | HIV-1-infection | HCV Coinfection | Buprenorphine Dependence | Methadone Dependence | Co-infectionCanada
Clinical Trials on MAT taper with galantamine
-
Beth Israel Deaconess Medical CenterUniversity of Pittsburgh; University of California, San FranciscoRecruitingInsomnia | Anxiety | Benzodiazepine UseUnited States
-
Zimmer BiometRecruitingHip Pain Chronic | Hip Fractures | Hip Injuries | Hip Disease | Hip ArthritisUnited States
-
Universidad Europea de MadridCompleted
-
VA Office of Research and DevelopmentRecruitingVancomycin | Clostridium | Difficile | FidaxomicinUnited States, Puerto Rico
-
Renmin Hospital of Wuhan UniversityHubei Hospital of Traditional Chinese Medicine; Wuhan Central Hospital; The Third... and other collaboratorsCompletedBowel Preparation Before ColonoscopyChina
-
Okayama Research Investigator Organizing NetworkUnknownCritical Illness | Pneumonia, Ventilator-AssociatedJapan
-
Krankenhaus Barmherzige Schwestern LinzTerminatedSolid Tumours | Adjuvant Chemotherapy | Port-A-CathAustria
-
University Hospital, Clermont-FerrandRecruiting
-
Teva Neuroscience, Inc.Completed
-
Ohio State University Comprehensive Cancer CenterNovartis; CelgeneCompletedRecurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin LymphomaUnited States